4.7 Article

Diagnostic Utility of Gold Coast Criteria in Amyotrophic Lateral Sclerosis

Journal

ANNALS OF NEUROLOGY
Volume 89, Issue 5, Pages 979-986

Publisher

WILEY
DOI: 10.1002/ana.26045

Keywords

-

Funding

  1. Motor Neuron Disease Research Institute of Australia
  2. National Health and Medical Research Council of Australia [510233, 1024915, 1055778, 1037746]

Ask authors/readers for more resources

The study found that the Gold Coast criteria had high sensitivity in the diagnosis of ALS, with consistent accuracy across different subgroups based on disease origin, duration, and functional impairments. In atypical ALS phenotypes, the Gold Coast criteria showed higher sensitivity and specificity.
Objective The diagnosis of amyotrophic lateral sclerosis (ALS) remains problematic, with current diagnostic criteria (revised El Escorial [rEEC] and Awaji) being complex and prone to error. Consequently, the diagnostic utility of the recently proposed Gold Coast criteria was determined in ALS. Methods We retrospectively reviewed 506 patients (302 males, 204 females) to compare the diagnostic accuracy of the Gold Coast criteria to that of the Awaji and rEEC criteria (defined by the proportion of patients categorized as definite, probable, or possible ALS) in accordance with standards of reporting of diagnostic accuracy criteria. Results The sensitivity of Gold Coast criteria (92%, 95% confidence interval [CI] = 88.7-94.6%) was comparable to that of Awaji (90.3%, 95% CI = 86.69-93.2%) and rEEC (88.6, 95% CI = 84.8-91.7%) criteria. Additionally, the Gold Coast criteria sensitivity was maintained across different subgroups, defined by site of onset, disease duration, and functional disability. In atypical ALS phenotypes, the Gold Coast criteria exhibited greater sensitivity and specificity. Interpretation The present study established the diagnostic utility of the Gold Coast criteria in ALS, with benefits evident in bulbar and limb onset disease patients, as well as atypical phenotypes. The Gold Coast criteria should be considered in clinical practice and therapeutic trials. ANN NEUROL 2021

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available